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Introduction
Sepsis is a syndrome of systemic inflammation arising
from infection that constitutes a top-ten cause of adult
mortality. The recent withdrawal of a specific sepsis thera-
peutic has diminished pharmaceutical enthusiasm for
developing novel drugs in this domain. Angiopoietin-2
(Angpt-2) is an endothelial-derived protein that potenti-
ates vascular inflammation and permeability and may be
involved in sepsis pathogenesis.
Objectives
We set out to screen well-established drugs for their
Angpt-2 lowering potential to ameliorate sepsis morbidity
and to analyse the underlying molecular mechanism.
Methods
In vitro
FDA-approved library screening in human umbilical vein
endothelial cells (HUVECs) and confirmation via Angpt-2
ELISA and quantitative RT-PCR.
In vivo
Murine experimental sepsis was induced both by endo-
toxin (LPS) and cecal ligation and puncture (CLP). Mice
were either treated with an Angpt-2 specific siRNA, sim-
vastatin, or both and survival as well as the direct effect on
Angpt-2 production was assessed by RT-PCR. In men: We
analyzed circulating Angpt-2 levels in a retrospective
matched case-control study in individuals with septic
shock.
Results
We found that simvastatin reduced endothelial Angpt-2
release and transcription in a time- and dose dependent
manner in HUVECs. This effect required Simvastatin’s
HMG-CoA reductase activity. Similarly, in vivo simvasta-
tin reduced the transcription of Angpt-2 murine lungs. In
septic mice, specific inhibition of Angpt-2 in the pulmon-
ary endothelium via an RNAi approach improved survival
by 50% (p=0.002). Simvastatin equally improved survival,
but the combination of Angpt-2 siRNA and simvastatin
showed no additive benefit indicating that simvastatin
might act via Angpt-2 inhibition. To investigate a poten-
tial link between statins and Angpt-2 in humans, we per-
formed a matched case-control study in critically ill
subjects and found that prior statin use was associated
with lower circulating Angpt-2.
Conclusions
In an unbiased approach Simvastatin was found to inhibit
Angpt-2 production in vitro. This observation could be
confirmed in vivo in different murine models of the dis-
ease. Our data indicate that a potential beneficial effect of
prior statin use in septic humans might be promoted via
the Angpt-2/Tie2 axis. Therefore, “point of care” screening
for circulating Angpt-2 in candidates for a clinical sepsis
trial might help to identify those individuals that benefit
from a statin treatment.
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